MedTrace Logo

Effect of Chemotherapy on PD-L1 in NSCLC

NCT03701607 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2018-10-10

No results posted yet for this study

Summary

PD-L1 is identified as an important biomarkers for predicting PD-1/PD-L1 inhibitors in advanced Non-Small Cell Lung Cancer. Several previous clinical trials have demonstrated that chemotherapy could enhance the efficacy of PD-1/L1 immunotherapy in NSCLC such as Checkmate-227, Impower-150, Keynote-189, etc. Pre-clincial experiment shows that chemotherapy could increase CD8 TIL infiltration in tumor microenvironment, activate T cell immune reaction. However, it remains unclear whether chemotherapy could affect PD-L1 in advanced NSCLC patients. The present study aims to evaluate whether PD-L1 will change after receiving chemotherapy in advanced NSCLC patients.

Conditions

  • Chemotherapy
  • Immunotherapy
  • PD-L1

Interventions

OTHER

PD-L1 group

PD-L1 expression is evaluated using immunohistochemical assay

Sponsors & Collaborators

  • Baodong Qin

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2019-02-28
Completion
2019-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03701607 on ClinicalTrials.gov